4D Molecular Therapeutics (FDMT) Change in Account Payables (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Change in Account Payables data on file, last reported at $3.5 million in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 1603.4% year-over-year to $3.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 15832.84% increase from a year earlier, with the FY2025 full-year figure at $6.8 million, up 677.61% from the prior year.
• Change in Account Payables for Q1 2026 stood at $3.5 million, down from $4.3 million in the prior quarter.
• Over the last five years, Change in Account Payables for FDMT reached as high as $4.5 million in Q2 2025 and fell as low as -$1.8 million in Q3 2025.
• Historically, Change in Account Payables has averaged $613823.5 across 5 years, with a median of $226000.0 in 2022.
• Across the five-year window, Change in Account Payables tumbled 313.46% in 2022 and surged 1603.4% in 2026, its largest moves.
• Year by year, Change in Account Payables stood at $1.5 million in 2022, then sank by 171.91% to -$1.1 million in 2023, then surged by 234.38% to $1.5 million in 2024, then surged by 193.84% to $4.3 million in 2025, then fell by 17.76% to $3.5 million in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were $3.5 million in Q1 2026, $4.3 million in Q4 2025, and -$1.8 million in Q3 2025.